ZNTL ZNTL
Company Profile ↓Company Overview
ZNTL (ZNTL) is a publicly traded company listed on with a market capitalization of $216.24M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.17.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -100.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -100.00% |
Stock Price Performance
| 1 Year: | +95.62% |
| 6 Months: | +15.50% |
| 3 Months: | -17.20% |
| 1 Month: | -12.08% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)30.00 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 52.6% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 40.56M | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 37.83M | 36.06M | 33.73M | 37.39M | 37.85M |
| Operating Income | -8.72M | -10.63M | -12.58M | -14.90M | -16.40M | -27.38M | -34.77M | -40.24M | -50.35M | -55.13M | -62.87M | -48.19M | -57.88M | -63.46M | -54.19M | -64.95M | -103.92M | -62.72M | -24.77M | -65.15M | -51.43M | - | -37.83M | -36.06M | -33.73M | -37.39M | -37.85M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -37.56M | -35.90M | -33.57M | -37.24M | -37.70M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -48.28M | -26.87M | -26.69M | -34.77M | -35.23M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 442.00K | 120.00K |
| Net Income | -8.34M | -10.47M | -12.34M | -14.51M | -16.13M | -26.86M | -34.55M | -40.30M | -49.90M | -54.57M | -4.19M | -50.06M | -59.08M | -68.36M | -54.40M | -63.22M | -112.53M | -55.53M | 10.07M | -88.28M | -40.16M | - | -48.28M | -26.87M | -26.69M | -35.22M | -35.35M |
| Diluted EPS | - | - | - | - | -2.88 | -0.78 | -0.91 | -1.01 | -1.24 | -1.34 | -0.09 | -1.11 | -1.31 | -1.34 | -0.96 | -1.07 | -1.85 | -0.79 | 0.14 | -1.24 | -0.56 | - | -0.67 | -0.37 | -0.37 | - | -0.50 |
| R&D Expense | 7.09M | 8.69M | 10.74M | 11.87M | 13.26M | 17.45M | 24.67M | 29.52M | 38.39M | 44.77M | 54.00M | 38.44M | 46.11M | 43.83M | 42.18M | 48.58M | 42.68M | 46.77M | 49.59M | 48.39M | 36.82M | - | 27.25M | 27.61M | 22.95M | - | 28.72M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 0 | 0 | 67.42M | 0 |
| Cost of Revenue | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | 227.29M | 253.94M | 254.88M | 145.01M |
| Operating Income | -46.84M | -118.79M | - | -227.29M | -253.94M | -187.46M | -145.01M |
| EBITDA | - | - | - | -225.86M | -252.55M | -186.17M | -144.27M |
| Interest Expense | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | -221.30M | -276.89M | -165.69M | -136.62M |
| Tax Provision | - | - | - | -469.00K | -601.00K | 177.00K | 442.00K |
| Net Income | -45.66M | -117.84M | - | -236.81M | -292.19M | -165.84M | -137.06M |
| Diluted EPS | -8.16 | -4.19 | - | -4.48 | -4.47 | -2.33 | -1.91 |
| R&D Expense | 38.39M | 84.90M | 175.60M | 172.73M | 189.59M | 167.77M | 107.30M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 87.48M | 365.56M | - | 539.31M | 551.69M | 430.34M | 288.97M |
| Current Assets | - | - | - | - | 451.93M | 496.72M | 386.07M | 253.19M |
| Cash & Equivalents | - | 67.25M | 54.95M | - | 43.07M | 28.04M | 33.90M | 35.99M |
| Inventory | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | 4.00K | - | - | - | - |
| Total Liabilities | - | 19.06M | 32.18M | - | 105.29M | 114.30M | 93.15M | 72.76M |
| Current Liabilities | - | 14.90M | 28.60M | - | 56.65M | 69.37M | 52.73M | 36.56M |
| Long Term Debt | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | 45.17M | 43.15M | 39.58M | 35.70M |
| Total Equity | 32.31M | -73.28M | 333.38M | - | 433.80M | 437.28M | 337.19M | 216.20M |
| Shares Outstanding | - | - | - | - | 59.28M | 70.77M | 71.28M | 69.09M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -39.14M | -86.83M | - | -163.75M | -207.82M | -170.86M | -125.25M |
| Investing Cash Flow | -352.00K | -284.83M | - | -114.18M | -44.46M | 176.56M | 131.62M |
| Financing Cash Flow | 81.83M | 360.44M | - | 261.04M | 237.30M | 108.00K | -4.28M |
| Capital Expenditure | -352.00K | -758.00K | -6.11M | -2.55M | -583.00K | -221.00K | - |
| Free Cash Flow | -39.49M | -87.58M | - | -166.30M | -208.41M | -171.08M | -125.25M |
| Net Change in Cash | - | - | - | -16.89M | -14.98M | 5.81M | 2.09M |
| Share Buybacks | - | - | - | - | 0 | 0 | 9.98M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | -278.0% | - |
| Net Margin % | - | - | - | - | - | -246.0% | - |
| ROE % | 62.3% | -35.3% | - | -54.6% | -66.8% | -49.2% | -63.4% |
| ROCE % | -64.5% | -35.3% | - | -47.1% | -52.6% | -49.6% | -57.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | 5AM Venture Management, LLC | 5.51% | 3.95M | $15.00M |
| 2 | Blackrock Inc. | 5.24% | 3.75M | $14.26M |
| 3 | Squadron Capital Management LLC | 5.16% | 3.70M | $14.06M |
| 4 | Two Sigma Investments, LP | 4.22% | 3.02M | $11.49M |
| 5 | Vanguard Capital Management LLC | 3.96% | 2.84M | $10.78M |
| 6 | Acadian Asset Management. LLC | 3.74% | 2.68M | $10.19M |
| 7 | Citadel Advisors Llc | 3.21% | 2.30M | $8.73M |
| 8 | Renaissance Technologies, LLC | 2.25% | 1.61M | $6.11M |
| 9 | Opaleye Management Inc. | 1.97% | 1.41M | $5.37M |
| 10 | Orbimed Advisors LLC. | 1.94% | 1.39M | $5.28M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ZNTL
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven …
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven …
Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL) (“Zentalis” or the “Company”), a clinical oncology innovator advancing late-stage development of an investigational, potentially first-in-class WEE1…
Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering
SAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL) (“Zentalis” or the “Company”), a clinical oncology innovator advancing late-stage development of an investigational, potentially first-in-class WEE1…
ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally?
Zentalis shares climb 28% over the past three months as optimism builds around azenosertib's ovarian cancer program.
Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026
Rapid oral presentation to highlight overall survival data from the DENALI Part 1b study of azenosertib SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing lat…
ZNTL — Frequently Asked Questions
What is the current share price of ZNTL?
As of 2026-09-16 18:39 PDT, ZNTL trades at $3.13 on NASDAQ/NYSE. Its 52-week range is $1.28 to $6.61.
What is the market capitalisation of ZNTL?
ZNTL has a market capitalisation of $216.24M on NASDAQ/NYSE.
What is the P/E ratio of ZNTL?
ZNTL trades at a trailing price-to-earnings (P/E) ratio of -1.64. Its price-to-book (P/B) ratio is 1.35.
What is the return on equity (ROE) of ZNTL?
ZNTL has a return on equity (ROE) of -63.39%. Its return on capital employed (ROCE) is -57.45%.
Is ZNTL a good stock to buy?
This page provides a data-driven analysis of ZNTL, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.